![]()
|
Figure 5 ELISA Validation with SARS-CoV-2 (COVID-19) Nucleocapsid Recombinant ProteinAntibodies: SARS-CoV-2 (COVID-19) Nucleocapsid antibody, 9099 (1 &956,g/mL). A direct ELISA was performed using SARS-CoV-2 (COVID-19) Nucleocapsid recombinant protein as coating antigen and the anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody as the capture antibody. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:20000 dilution. Detection range is from 0.3 ng/mL to 1000ng/mL. |
![]()
|
Figure 6 ELISA Validation with SARS-CoV-2 (COVID-19) Nucleocapsid Recombinant ProteinAntibodies: SARS-CoV-2 (COVID-19) Nucleocapsid antibody, 9099 (1 &956,g/mL). A direct ELISA was performed using SARS-CoV-2 (COVID-19) Nucleocapsid recombinant protein (10-306) as coating antigen and the anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody as the capture antibody. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:20000 dilution. Detection range is from 8 ng/mL to 1000ng/mL. |
![]()
|
Figure 1 Immunohistochemistry Validation of SARS-CoV-2 (COVID-19) Nucleocapsid in Human Lung Tissue from the COVID-19 Patient (Sun et al., 2020) Detection of SARS-CoV-2 nucleocapsid protein by anti-SARS-COV-2 nucleocapsid antibodies (9099, 0.02 &956,g/mL, A,B) or SARS-CoV-2 Spike S1 antibodies (9083, 1 &956,g/mL D,E) in adjacent sections of autopsy lung tissue from COVID-19 deceased patient. Negative control staining on autopsy lung tissue from patient who died from non-COVID-19 pneumonia is shown for Nucleocapsid protein (C) or Spike protein (F). Negative control using normal rabbit immunoglobulin on COVID-19 autopsy tissue is presented (G). DAB chromogen and hematoxylin counterstain are used. Scale bars: 50µM in A, C, D, F, G, 20&956,M in B and E. |
![]()
|
Figure 2 Immunohistochemistry Validation of SARS-CoV-2 (COVID-19) Nucleocapsid in Human Lung Tissue from the COVID-19 Patient Immunohistochemical analysis of paraffin-embedded COVID-19 patient lung tissue using anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody (9099, 0.02 &956,g/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT, antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4&730,C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. (Courtesy of Dr. Hallgeir Rui, MCW) (Picture shown in 40X magnification) |
![]()
|
Figure 3 Immunohistochemistry Validation of SARS-CoV-2 (COVID-19) Nucleocapsid in Human Lung Tissue from the COVID-19 Patient Immunohistochemical analysis of paraffin-embedded COVID-19 patient lung tissue using anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody (9099, 0.02 &956,g/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT, antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4&730,C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. (Courtesy of Dr. Hallgeir Rui, MCW) (Picture shown in 63X magnification) |
![]()
|
Figure 4 Western Blot Validation with SARS-CoV-2 (COVID-19) Nucleocapsid Recombinant ProteinLoading: 50 ng per lane of SARS-CoV-2 (COVID-19) Nucleocapsid recombinant protein. Antibodies: SARS-CoV-2 (COVID-19) Nucleocapsid, 9099, 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Lane 1: 0.5 &956,g/mL, Lane 2: 1 &956,g/mL and Lane 3: 2 &956,g/mL. |
